Editorials

Balancing the intended and unintended effects of statins

BMJ 2010; 340 doi: http://dx.doi.org/10.1136/bmj.c2240 (Published 20 May 2010) Cite this as: BMJ 2010;340:c2240
  1. Alawi A Alsheikh-Ali, consultant cardiologist1,
  2. Richard H Karas, executive director2
  1. 1Institute of Cardiac Sciences, Sheikh Khalifa Medical City, Abu Dhabi, United Arab Emirates
  2. 2Molecular Cardiology Research Institute, Tufts Medical Center and Tufts University School of Medicine, Boston, MA 02111, USA
  1. aalsheikhali{at}alum.mit.edu

    When used according to guidelines, the benefits outweigh the risks

    In the past quarter of a century, statins—inhibitors of 3-hydroxy-3-methylglutaryl coenzyme A reductase—have become one of the most studied and prescribed classes of drugs in modern history. The efficacy of these drugs in reducing cardiovascular morbidity and mortality across a wide spectrum of risk is supported by an extensive dataset of randomised controlled trials,1 which have been largely reassuring about the safety of currently available types of statin. However, safety data from trials are inherently incomplete, given the relatively short follow-up periods of clinical trials and their limited external validity. In the linked paper (doi:10.1136/bmj.c2197), Hippisley-Cox and Coupland used routinely collected data on more than two million men and women from 368 general practices in England and Wales to estimate the association of type, dose, and duration of statin use with the occurrence of several end points.2 By using a large database they overcome the problem of the low incidence of statin associated adverse events, and they provide information on adverse effects that clinical trials are not adequately …

    View Full Text

    Sign in

    Log in through your institution

    Free trial

    Register for a free trial to thebmj.com to receive unlimited access to all content on thebmj.com for 14 days.
    Sign up for a free trial

    Subscribe